Mechanisms of childhood obesity underlying the susceptibility to multisystem inflammatory syndrome in children (MIS-C)
Mechanisms of childhood obesity underlying the susceptibility to multisystem inflammatory syndrome in children (MIS-C)
批准号:
10641777
负责人:
Janet Chou
金额:
$44.25万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-15 至 2024-06-30
关键词:
12 year old2019-nCoVAccountingAcuteAdultAutoimmune DiseasesBiologicalBiological MarkersBlood Coagulation DisordersBody mass indexBody measure procedureCOVID-19COVID-19 testCOVID-19 vaccineCellsChildChild CareChildhoodClinicCollaborationsCommunitiesComplicationCoronary AneurysmDataData AnalysesData SetDevelopmentDiseaseEducationEndocrinologyEuropeExanthemaExhibitsFeverFunctional disorderGenetic PolymorphismGenetic RiskGenetic ScreeningGenetic studyGoalsHematological DiseaseHospitalizationImmuneImmune responseImmunityInfectionInflammationInflammatoryInflammatory ResponseInterferonsLymphopeniaMediatingMetabolismMultiomic DataMultisystem Inflammatory Syndrome in ChildrenMyocardial dysfunctionObesityOnly ChildOverweightPatientsPhasePopulationPredispositionPrevalencePublic HealthPulmonary Heart DiseaseResearch PersonnelRiskRisk AssessmentRisk FactorsSARS-CoV-2 infectionSamplingSeveritiesShockSignal TransductionSymptomsSyndromeT-Cell ActivationT-LymphocyteTestingUnited StatesVaccine Clinical TrialVariantViralVirusVirus DiseasesWeightacute infectioncohortcomorbiditycytopeniadisorder riskgastrointestinal symptomgenetic risk factorgenetic variantimmune activationinsightmultiple omicsobesity geneticsobesity in childrenpost SARS-CoV-2 infectionsevere COVID-19
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
Unpredictability is the hallmark of Multisystem Inflammatory Syndrome in Children (MIS-C). MIS-C is a
severe pediatric complication of SARS-CoV-2 infection. MIS-C is distinct from COVID-19. It is not associated
with pre-existing cardiopulmonary, autoimmune, or hematologic disorders. It can occur either during acute phase
with detectable SARS-CoV-2 virus, or in the post-infectious period of several weeks after acute infection. Milder
symptoms of MIS-C include fevers, rashes, and gastrointestinal symptoms, but can progress to cytopenias,
coagulopathy, myocardial dysfunction, coronary aneurysms, and/or shock. We and others have found that MIS-
C is associated with pediatric overweight and obesity, thereby identifying over 380 million children at risk for this
disease. The mechanisms by which overweight and obesity influence the development of MIS-C are unknown.
Until a vaccine against SARS-CoV-2 is globally available to all children, they will remain vulnerable to MIS-C.
Our preliminary studies indicate that MIS-C is a highly inflammatory disease that incites more severe
immune cell activation than COVID-19, particularly in overweight and obese children. Overweight and obese
children with MIS-C had more T cell lymphopenia and T cell activation than their normal weight counterparts,
suggesting an increased risk for more severe disease. Deleterious genetic variants increasing IFN and
inflammatory signaling were exclusively found in patients with MIS-C, rather than severe COVID-19. This is a
mechanistic counterpoint to defective IFN signaling associated with severe COVID-19 in adults. Our central
hypothesis is that pediatric overweight and obesity prime interferon signaling, thereby increasing T cell
activation and ultimately, the risk of MIS-C
Aim 1 will elucidate how pediatric overweight and obesity drive immune cell dysfunction during MIS-C.
The proposed studies will test the hypotheses that pediatric overweight and obesity are associated with more
severe MIS-C, characterized by excessive interferon signaling and T cell activation.
Aim 2 will identify mechanistic risk factors for MIS-C. The proposed studies will test the hypothesis that,
even in the absence of infection, circulating immune cells from overweight and obese children exhibit an
increased interferon signature that promotes T cell activation. We will develop a strategy for stratifying MIS-C by
integrating genetic screening with measures of body mass index.
Building on collaborations spanning over a decade and unique cohorts of children with MIS-C and/or obesity,
our investigator team brings expertise in MIS-C, host immunity, pediatric obesity and endocrinology, and
multiomics. This project will generate causal insights of how overweight and obesity influence the development
and severity of MIS-C, with the goal of developing strategies for a population that remains at risk for this disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/ppul.25924
发表时间:
2022-07
期刊:
PEDIATRIC PULMONOLOGY
影响因子:
3.1
作者:
[Wobma, Holly, Perkins, Ryan, Bartnikas, Lisa, Dedeoglu, Fatma, Chou, Janet, Vleugels, Ruth Ann, Lo, Mindy S., Janssen, Erin, Henderson, Lauren A., Whangbo, Jennifer, Vargas, Sara O., Fishman, Martha, Krone, Katie A., Casey, Alicia]
通讯作者:
Casey, Alicia
Mechanisms of childhood obesity underlying the susceptibility to multisystem inflammatory syndrome in children (MIS-C)
-
批准号:10450145
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2021
-
负责人:Janet Chou
-
依托单位:
Mechanisms of pediatric overweight and obesity underlying susceptibility to multisystem inflammatory syndrome in children (MIS-C)
-
批准号:10544668
-
项目类别:
-
资助金额:$10.22万
-
财政年份:2021
-
负责人:Janet Chou
-
依托单位:
Mechanisms of childhood obesity underlying the susceptibility to multisystem inflammatory syndrome in children (MIS-C)
-
批准号:10319758
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2021
-
负责人:Janet Chou
-
依托单位:
Molecular Basis of Allergic and Immunologic Disease
-
批准号:10609496
-
项目类别:
-
资助金额:$75.62万
-
财政年份:1986
-
负责人:Janet Chou
-
依托单位:
国内基金
海外基金
登录
查看更多内容
微米和纳米塑料作用下2019-nCoV抗病毒药物利巴韦林对河蚬的毒性作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:郭晓宇
-
依托单位:
2019-nCoV感染导致人体淋巴细胞减低机制及其对机体免疫功能影响
-
批准号:82030002
-
项目类别:专项基金项目
-
资助金额:135万元
-
批准年份:2020
-
负责人:曹彬
-
依托单位:
基于人口流动大数据的新型冠状病毒(2019-nCoV)输出感染风险及接触网络传播模型研究
-
批准号:--
-
项目类别:--
-
资助金额:135万元
-
批准年份:2020
-
负责人:吕欣
-
依托单位:
云南驯养野生动物中新型冠状病毒(2019-nCoV)溯源调查与验证
-
批准号:--
-
项目类别:--
-
资助金额:140万元
-
批准年份:2020
-
负责人:夏雪山
-
依托单位:
新型冠状病毒(2019-nCoV)反向遗传系统及啮齿类感染模型的建立与应用
-
批准号:--
-
项目类别:--
-
资助金额:150万元
-
批准年份:2020
-
负责人:黄耀伟
-
依托单位:
血必净预防2019-nCoV肺炎发生ARDS及机制研究
-
批准号:82041003
-
项目类别:专项基金项目
-
资助金额:135万元
-
批准年份:2020
-
负责人:宋元林
-
依托单位:
新型冠状病毒2019-nCoV复制复合体关键蛋白的功能与潜在药物靶点研究
-
批准号:--
-
项目类别:专项基金项目
-
资助金额:150万元
-
批准年份:2020
-
负责人:郭德银
-
依托单位:
2019-nCoV蝙蝠及人群代表性流行株致病能力的比较研究
-
批准号:--
-
项目类别:专项基金项目
-
资助金额:150万元
-
批准年份:2020
-
负责人:周鹏
-
依托单位:
人新型冠状病毒2019-nCoV受体利用介导的种间传播和感染机制研究
-
批准号:--
-
项目类别:专项基金项目
-
资助金额:140万元
-
批准年份:2020
-
负责人:葛行义
-
依托单位:
2019-nCoV“不典型症状”感染者的宿主因素及其作用机制研究
-
批准号:--
-
项目类别:专项基金项目
-
资助金额:150万元
-
批准年份:2020
-
负责人:张文宏
-
依托单位: